Pathophysiology
A full understanding of Cl INH deficiency requires a brief review of the complement system ( Figure 1 ) (12,14-16). This system consists of approximately 20 proteins, many circulating as inactive enzyme precursors, with two pathways for activation: the classical pathway and the alternate pathway. The classical pathway is activated by antigen-antibody complexes, whereas the alternate pathway is activated by naturally occurring substances, such as bacterial cell walls and yeast walls (17, 18) . Complement activation by either pathway may result in opsonization (19), lysis (20), anaphylatoxin activity (21,22), chemotactic activity (23), and immune complex clearance (24).
Cl, the first component of the classical pathway of complement, exists in serum as a macromolecular complex containing one Clq, two Clr, and two Cls molecules (25). Activation of this macromolecule leads to cleavage of Cls to produce Clls, also called Cl esterase. Cl(s may then act on C4 and C2 to produce C4b2a in the fluid phase or on the cell, cleaving C4 and C2.
Control proteins limit the amount of complement activation. Cl INH is a single-chain, highly glycosylated a,-globulin, serine-protease inhibitor (SERPIN) that contains 478 amino acids and specifically inhibits the spontaneous activation of the first component of complement (3,4,15). Cl INH binds stoichiometrically (in a 1:l ratio) to Cllr and Clls and less well to their inactivated precursors, Clr and Cls (26-29). Individuals who lack sufficient Cl INH cannot adequately control the activation of Cl, which leads to the consumption of C4 and C2 with subsequent generation of C2 kinin or other biologically active products (8,30). C2 kinin alone or in conjunction with bradykinin or other substances may then cause increased vascular permeability and subcutaneous and mucosal swelling characteristic of HAE (3,15). The bradykinin receptor and genotype may have particular relevance to clinical status (31).
C4b2a formation and decay are controlled by complement receptor 1 (CRl, CD35) and C4 binding protein (C4BP), as well as factor I, which prevents C3 Natural History, Manifestations, and Clinical Presentation
The importance of recognizing HAE cannot be overemphasized. Frank et al. (13) reported that the interval between onset of symptoms and diagnosis is approximately 20 yr, probably because HAE is an uncommon disorder. In the United States, HAE has a probable incidence of approximately 1:50,000 to 1:150,000, although there are large regional differences related to the presence of afflicted families in certain parts of the country. Acquired Cl INH deficiency is probably less common than HAE, but its prevalence is unknown.
Compounding the rarity of the processes is the wide variety of presenting symptoms. Therefore, the natural history and clinical manifestation of Cl INH deficiency deserve careful attention. Most patients with this disorder have a family history (13). Age of onset is usually not helpful in making the diagnosis, but the disease manifests itself by the age of 30 yr in approximately 98% of patients (44). Although one half of patients with HAE are symptomatic by the age of 7 yr and two-thirds are symptomatic by the age of 13 yr (45), presentation after the age of 50 yr has been reported (13). Presenting signs are usually cutaneous edema, abdominal pain, vomiting, and edema of the laryngeal or retropharyngeal area. Attack duration typically ranges from approximately 24 h to several days. Minor or even trivial trauma or emotional upset are the most consistent and frequent precipitators of attack. Trauma may be the trigger of one half of exacerbations (13).
Unlike HAE, acquired Cl INH deficiency is associated with onset at an older age and absence of family history. In addition, acquired Cl INH deficiency may be associated with a lymphoproliferative disorder, such as lymphoma or systemic lupus erythematosis (43,46-48). HAE and acquired Cl INH deficiency are both characterized by the presence of angioedema and are not clearly distinguishable from each other on this basis (43). The swelling involves the deep dermis and is nonpruritic, nonerythematous, circumscribed, cutaneous, and asymmetric (3,40,49). Nearly one fourth of patients with HAE have a nonpruritic rash accompanying attacks of HAE, described as erythema marginatum (13,50). Although urticaria (erythematous, pruritic, cutaneous elevations of the skin that blanch with pressure) can occur in patients who have Cl INH deficiency, urticaria that is always associated with angioedema suggests a diagnosis other than HAE (12,51).
HAE characteristically involves the extremities, face, airway, and gastrointestinal tract. In the series reported by Frank et al. (13), 96% had swelling of extremities, 93% had recurrent abdominal pain, 85% had angioedema of the face, and 64% had oropharyngeal involvement. Attacks involving the airway present the greatest threat. Obstruction generally begins slowly with voice change and dysphagia. Often it is preceded by peripheral swelling (13), but facial edema has also been reported as the initial presenting sign (52). Although the differential diagnosis of airway and extremity swelling is quite extensive (Table l) , sudden airway compromise leading to the death of a relative should raise suspicion of HAE. Because HAE may also cause swelling during head and neck or dental surgery, the diagnosis should be made before these procedures are performed. Abdominal and orthopedic procedures may not trigger an attack unless the patient is also tracheally intubated, whereas dental surgery is more likely to provoke obstructive laryngeal edema in patients with Cl INH deficiency (13,45,53). Frank et al. (13) reported life-threatening pharyngeal swelling after dental surgery in many patients with untreated HAE.
In addition to swelling of the extremities and airway, the gastrointestinal tract is also vulnerable to attacks of HAE. Osler (2) wrote, "Associated with the edema, there is almost invariably gastrointestinal disturbance: colic, nausea, vomiting, and sometimes diarrhea." Unexplained episodic edema in a patient with recurrent abdominal pain or even ascites should raise suspicion of HAE (54 The abdominal pain caused by HAE is best characterized as crampy, colicky, and often excruciating (13,40). Usually patients have diffuse abdominal tenderness characterized by normal to high-pitched bowel sounds without rigidity and peritoneal signs (12). The pain may be secondary to intestinal obstruction caused by localized swelling (55), and the radiographic appearance is of stacked coins or a thumbprint (58). Loss of fluid from the gut wall into the lumen may result in vomiting and copious accompanying watery diarrhea often late in the course of attack (12,45). Diarrhea can be so severe as to cause hemoconcentration, hypotension, and shock (59). Significant extraluminal intraperitoneal fluid sequestration can also develop (59). Leukocytosis may be present (12,57).
Although attacks of HAE during pregnancy are unpredictable, the risk of an attack seems to decrease after the first trimester and during delivery (13). When attacks occur, however, they are often accompanied by acute abdominal pain mimicking acute appendicitis or peritonitis. HAE should be considered in the differential diagnosis of acute abdominal pain in pregnant patients when no other cause is apparent (45,60). Pregnancy may worsen symptoms of HAE, but the condition does not seem to adversely affect fetal viability. In one study, of 36 pregnancies, all were carried to term (44). Most women do not experience improvement at menopause (13, 61 
Management of Cl INH Deficiency Drug Therapies to Treat Cl INH Deficiency
The anesthesia literature provides only limited guidance regarding the management of patients with Cl INH deficiency (69-78). Therefore, we describe briefly the major therapies that have been used to treat HAE and how these medications are used under specific circumstances. e-Aminocaproic acid (EACA), an antifibrinolytic drug that inhibits plasminogen activation and plasmin activity, was once thought to be useful in long-term therapy of HAE (13,79,80). This drug probably acts primarily by limiting the formation of plasmin, which can activate Cl. EACA is not often used today because it may cause muscle ache, fatigue, postural hypotension, and thromboembolic events (1381). In one recent report, however, long-term use of EACA decreased the frequency and severity of symptoms in two patients with Cl inhibitor deficiency with no apparent side effects or toxicity (82). Tranexamic acid, another inhibitor of plasminogen activation and of plasmin, has also been used in the prophylaxis of HAE (83,84). It may limit the activation of Cl, but it is rarely used (42,45).
In 1960, Spaulding (85) demonstrated that chronic therapy with methyltestosterone may be useful in the long-term treatment of HAE. Androgens such as methyltestosterone, danazol, and stanozolol act by increasing the synthesis of Cl INH by the liver (42,86). Attenuated androgens are clearly effective in preventing attacks but may cause serious adverse events including weight gain, headaches, myalgias, menometrorrhagia, amenorrhea, alopecia, acne, altered libido, liver disease, hirsutism, and virilization (45). These events have limited androgen use, especially use of methyltestosterone. Danazol may also be hazardous in pregnant patients and children secondary to gonadal effects (13). Currently, stanozolol is the therapeutic mainstay (2 m -5 * jwl * d-i initially and then 0.5-6.0 mg * kg * d i) as required to control attacks. In general, the final dose of androgen that is selected prevents serious attacks but still allows mild attacks (such as mild swelling of an extremity) to occur occasionally. Patients receiving anabolic steroids should undergo routine liver function testing approximately every 6 mo.
Fresh-frozen plasma (FFP) contains Cl INH but also contains the kinins and substrates (including uncleaved C2 and C4) that may fuel complement activation (see below). FFP therapy also presents a risk of infection by blood borne pathogens.
Although anabolic steroids and FFP are currently the chief therapies for Cl INH deficiency, purified Cl INH concentrate is one of the most promising therapies for the future. Cl INH has been available commercially only in Europe since the 1980s (ClInactivator HS; Behring, Marburg, Germany). From its use there, we know that lyophilized Cl INH concentrate can effect partial resolution of symptoms within 1 h and complete resolution within 24 h. Cl INH is obtained from pooled human plasma, and the usual dose is 25 U/kg. Appropriate administration can increase Cl INH levels by 50% in adults over 15 min @Oh Cl INH concentrate offers specific rapid therapy and can be used to treat acute attacks. It may also be used for acute prophylaxis for which the efficacy of other treatments is more problematic. Disadvantages include lack of availability in the United States, expense, the need for IV administration, and concern about transmission of hepatitis or human immunodeficiency virus. Regarding the latter concern, Cl INH concentrate must be tested to assure that it does not transmit a virus. Currently, Cl INH concentrate has not been approved by the Food and Drug Administration for use in the United States and is only available on an investigational basis (78). After infusion, Cl INH concentrate can be effective within 15 min and may be protective for approximately 2 days (80), or perhaps longer. Its efficacy during the induction of labor and for tonsillectomy have also been described (76,78).
Chronic Prophylaxis
Prophylactic therapy is given to prevent airway obstruction or when the frequency of attacks is greater than once or twice per month and is severe enough to require treatment (80). Danazol and stanozolol maintenance therapy have clearly been shown to prevent attacks. A typical oral adult dose is 2 mg/d stanozolol or 600 mg/d danazol. Patients with acquired Cl INH deficiency may need much larger doses than those given to patients with HAE.
Prophylaxis Before Elective Surgical Procedures
Before elective surgical procedures, patients with HAE may be given stanozolol (78), FFP (13,72,87) or Cl INH concentrate (78,88,89). Stanozolol has been used alone or in combination with other therapies (78). Stanozolol is typically given 4 mg four times a day for 5-7 days before scheduled surgery. FFP may be given several hours or the evening before dental procedures 
Special Anesthetic Considerations
Anesthesiologists must be prepared to manage the airway of patients with HAE in three settings: electively, when the airway is not compromised; urgently, when mild or moderate airway edema is present; and emergently, when airway swelling is life-threatening.
In the elective surgical setting, monitored, regional, or general anesthesia can be performed safely (69). The presence of angioedema does not influence drug choices for the induction of either general or regional anesthesia or the use of muscle relaxants, including succinylcholine (69). There are no known constraints regarding the use of any of the volatile anesthetics.
It is important to avoid manipulation of the airway as much as possible by relying on regional or inhalation techniques. These obviate the need for the pressure and traction resulting from laryngoscopy and eliminate one important trigger for an attack. Abada and Owens (71) reported the successful use of spinal anesthesia for a urologic procedure, and Schar (73) reported a mask inhalation technique using no form of artificial airway.
Regional and mask inhalation techniques are certainly safe and offer some theoretical advantage. However, endotracheal intubation is not necessarily contraindicated or, under proper circumstances, hazardous (69). The role of the laryngeal mask airway in the these patients is not completely clear, but it is reasonable to assume that its larger surface contact area may lead to worsened airway edema. When intubation is necessary, so is heightened awareness; perhaps some form of prophylaxis should also be given. There are no universally accepted guidelines, but the administration of anabolic steroids for 5-7 days before surgery, as described above, and Cl INH concentrate (or FFP if concentrate is not available) immediately before surgery are most often used.
These treatments make intubation generally safe, but they may not be completely protective. This was suggested by a report of a mild generalized flare of angioedema in a 15-yr-old male patient with HAE after tonsillectomy who had been treated prophylactically the week before surgery with stanozolol (4 mg four times daily) and then IV Cl INH concentrate just before surgery.
Patients with HAE can usually be tracheally intubated safely, but they require close observation even after prophylactic premeditation with stanozolol and Cl INH concentrate (78). Unless the surgical procedure dictates surgical intensive care, this is not generally necessary (69).
Patients with HAE who are hemodiluted and undergo cardiopulmonary bypass (CPB) require extra diligence. One case report describes a patient with acquired Cl INH deficiency with a preoperative Cl INH level of 30% of normal who underwent CPB. Apparently, hemodilution during surgery reduced these levels even further, and the patient died intraoperatively of symptoms related to uncontrolled complement activation (74). In contrast, in another similar case, the Cl INH level increased to approximately 75% of normal after stanozolol therapy preoperatively, and the patient underwent uneventful CPB with a membrane oxygenator (75). The acceptable lower preoperative limit for Cl INH is not clear, but 50% of normal has been suggested (98).
When HAE attacks involve the airway, the anesthesiologist may be called on to render emergency care. In cases of mild airway edema, symptoms can resolve without further treatment, usually within a few days. Patients should be carefully observed in the hospital. Oxygen therapy may be provided, and oxygenation should be monitored using pulse oximetry. In extreme distress, ventilation via a mask followed by immediate tracheal intubation is warranted.
The use of muscle relaxants is inadvisable if the patient demonstrates the ability to maintain even marginal oxygenation. When performing emergency laryngoscopy and intubation, the attendance of an otolaryngologist is mandatory should a tracheostomy be necessary. The laryngeal mask airway has no established or demonstrated role in this setting and, given the potential for laryngeal distortion secondary to edema, would probably be ineffective in most cases. The presence of severe airway swelling and the demand for acute intervention can greatly limit the effectiveness of fiberoptic intubation. Instrumentation of the airway is best performed in the operating room, in which full resuscitative measures can most readily be undertaken. This may not always be possible, and the risk of transport from the emergency room to the operating room certainly must be assessed on the basis of the rapidity of progression of airway compromise.
If this risk is deemed unacceptable, an emergency tracheostomy should be performed without delay. Airway swelling may become so severe that even tracheostomy may be ineffective in providing a patent airway. Swelling may extend into the airway to such an extent that death is inevitable in the absence of specific therapy (Cl INH replacement).
